Research programme: diabetes and obesity therapeutics - GenfitAlternative Names: G 220; MKG 02; TGFTX 2
Latest Information Update: 30 Mar 2009
At a glance
- Originator Genfit; Merck Sante
- Developer Genfit
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus